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Introduction
Adults with acute myeloid leukemia (AML) have a poor
prognosis with conventional chemotherapy agents. There are
approximately 18,000 new cases of AML with close to 11,000
deaths yearly in the United States.1 Unfortunately, treatment of
AML has changed little over the last four decades. “7+3” [7 days
of continuous infusion (CI) cytarabine and 3 days of anthracy-
cline] remains the standard induction chemotherapy regimen
for newly diagnosed non-acute promyelocytic leukemia (APL)
AML patients who are fit for intensive therapy.2 Despite many
attempts to improve the 7+3 regimen with the addition and/or
substitution of mechanistically diverse agents, no regimen has
proven to be consistently superior to 7+3.3
Timed sequential therapy (TST) has been shown to
improve outcomes in some newly diagnosed adults and chil-
dren with AML.4-8 TST relies on the opportune timing of cell-
cycle specific cytotoxic agents in order to exert maximal
effect on leukemic cell death. In vitro studies of flavopiridol, a
pan cyclin-dependent, multi-serine-threonine kinase
inhibitor, followed by cytarabine in a TST manner demon-
strated increased cytotoxicity compared to either agent
alone.9 FLAM (flavopiridol followed by cytarabine and mitox-
antrone) was evaluated in 138 newly diagnosed poor-risk
AML patients in serial phase II trials, with overall complete
remission (CR) rates of 67%-80% and reproducibly low rates
of morbidity and mortality.10-12 These data suggest that FLAM
might improve outcomes relative to 7+3 induction therapy in
newly diagnosed AML patients. Therefore, we sought to
compare FLAM to 7+3 in a multicenter randomized phase II
trial in newly diagnosed adult AML patients with intermedi-
ate- and adverse-risk cytogenetics.
Methods 
Patient eligibility
Between May 2011 and July 2013, newly diagnosed AML patients
aged 18-70 years with pathological confirmation of bone marrow
(BM) blasts 20% or more were enrolled in a multi-institutional study.
Eligibility criteria were similar to those from previous studies.10-12 FISH
©2015 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.125849
The online version of this article has a Supplementary Appendix.
Manuscript received on February 16, 2015. Manuscript accepted on May 21, 2015.
Correspondence: joshua_zeidner@med.unc.edu
Serial studies have demonstrated that induction therapy with FLAM [flavopiridol (alvocidib) 50 mg/m2 days 1-3,
cytarabine 667 mg/m2/day continuous infusion days 6-8, and mitoxantrone (FLAM) 40 mg/m2 day 9] yields com-
plete remission rates of nearly 70% in newly diagnosed poor-risk acute myeloid leukemia. Between May 2011-
July 2013, 165 newly diagnosed acute myeloid leukemia patients (age 18-70 years) with intermediate/adverse-risk
cytogenetics were randomized 2:1 to receive FLAM or 7+3 (cytarabine 100 mg/m2/day continuous infusion days
1-7 and daunorubicin 90 mg/m2 days 1-3), across 10 institutions. Some patients on 7+3 with residual leukemia on
day 14 received 5+2 (cytarabine 100 mg/m2/day continuous infusion days 1-5 and daunorubicin 45 mg/m2 days 1-
2), whereas patients on FLAM were not re-treated based on day 14 bone marrow findings. The primary objective
was to compare complete remission rates between one cycle of FLAM and one cycle of 7+3. Secondary end points
included safety, overall survival and event-free survival. FLAM led to higher complete remission rates than 7+3
alone (70% vs. 46%; P=0.003) without an increase in toxicity, and this improvement persisted after 7+3+/-5+2
(70% vs. 57%; P=0.08). There were no significant differences in overall survival and event-free survival in both
arms but post-induction strategies were not standardized. These results substantiate the efficacy of FLAM induc-
tion in newly diagnosed AML. A phase III study is currently in development. This study is registered with clinical-
trials.gov identifier: 01349972.
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ABSTRACT
for core-binding factor (CBF) AML (t(8;21); inv(16); (t(16;16)) was
performed at each institution prior to enrollment, and patients
were excluded if CBF positive. The study was conducted in accor-
dance with the Declaration of Helsinki after approval by the ethics
committee of each participating center. 
Treatment
Patients were randomized by centralized computer-generated
allocation procedure (REDCap13) 2:1 to receive FLAM (arm A):
flavopiridol 50 mg/m2 IV days 1-3, cytarabine 2 gm/m2 CI IV days
6-8 (667 mg/m2/day), and mitoxantrone 40 mg/m2 IV day 9 or 7+3
(arm B): cytarabine 100 mg/m2/day CI IV days 1-7, and daunoru-
bicin 90 mg/m2 IV days 1-3 (idarubicin 12 mg/m2 IV days 1-3 was
substituted as needed for lack of daunorubicin availability).
Patients were stratified according to the following risk factors: 1)
age 50 years or over; 2) secondary AML (defined as treatment-
related AML or AML from antecedent hematologic disorder)
and/or known adverse cytogenetics;14 and 3) hyperleukocytosis
[white blood cell (WBC) count >50x109/L]. 
All patients received a BM biopsy on day 14 unless medically
contraindicated. Residual leukemia on day 14 was defined as BM
blasts 5% or more morphologically with overall cellularity 10% or
more.  Arm B patients were eligible to receive an additional cycle
of induction therapy, 5+2 (cytarabine 100 mg/m2/day CI IV days
1-5, daunorubicin 45 mg/m2 IV days 1-2) in the setting of residual
leukemia on day 14. Post-induction treatment was performed
according to physician preference. 
Response and toxicity
Bone marrow (BM) aspirates and biopsies were performed
before treatment, on day 14 of treatment, and at hematologic
recovery or when leukemia regrowth was suspected. Response
criteria were defined according to standard definitions.14 Adverse
events were graded by NCI Common Terminology Criteria for
Adverse Events (CTCAE) v. 4.0. 
Statistical analysis
The study was designed to compare CR rates between FLAM
and one cycle of 7+3, using a Bayesian approach for interim mon-
itoring for futility. The primary analysis would conclude a signifi-
cant benefit for FLAM if the one-sided P value from a Fisher’s
exact test less than 0.10. A sample size of 165 patients, random-
ized 2:1 to FLAM or 7+3, respectively, yielded 85% power to
detect an increase in the probability of CR from 55% 
with 7+315-17 to 75% with FLAM. In addition to the planned pri-
mary end point analysis, CR rates between FLAM and 7+3+/-5+2
were analyzed by Fisher's exact test with a one-sided P value anal-
ogous to the primary end point analysis. 
Secondary end points included toxicity comparisons, overall
survival (OS), and event-free survival (EFS). OS was defined from
date of randomization to death or last known follow up. EFS was
defined as date of randomization to the first occurrence of persist-
ent AML after one cycle of induction, relapse or death. Patients
were censored for EFS if they had received non-protocol therapy
or an allogeneic stem cell transplant (SCT). All significance tests for
secondary end points were two-sided with P<0.05 considered sig-
nificant. To explore heterogeneity of treatment effects between
various subgroups, logistic regression models with terms for treat-
ment, the patient subgroup, and their interaction were fit. P values
were derived from likelihood ratio tests and are considered
exploratory. OS, EFS, and time to hematologic recovery probabil-
ities were calculated using the Kaplan-Meier method and tested
for differences between treatment arms with the log rank test.
Further details of Methods are provided in the Online
Supplementary Appendix.
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Figure 1. Consort Diagram. 172 patients were ran-
domized between FLAM (n = 114) and 7+3 (n =
58), 109 patients on FLAM and 56 patients on
7+3 were analyzed for response and overall sur-
vival (OS). 12 patients did not receive FLAM after
randomization: progressive deterioration of per-
formance status (n=1), exceeded maximum prior
anthracycline dose (n=1) 22 patients did not
receive 7+3 after randomization: withdrawal of
consent (n=1), death before intervention (n=1). 33
patients were excluded from the analysis after ini-
tiating treatment with FLAM due to ineligibility: T-
cell acute lymphoblastic leukemia (n=1),
Favorable-risk cytogenetics: t(8;21) (n=1), Prior
treatment for AML (n=1). 47 patients treated with
FLAM and one patient treated with 7+3 were non-
evaluable (NE) for response due to early death.  
Results 
Patients’ characteristics
One hundred and sixty-five patients (FLAM: n=109,
7+3: n=56) from 10 institutions were randomized, treated,
and included in the analysis, as shown in Figure 1. Clinical
demographics and disease biological features of all
patients are presented in Table 1. Adverse-risk according
to ELN criteria14 was seen in 44% and 38% of patients on
FLAM and 7+3, respectively. In addition, 47% of patients
(FLAM: 48%, 7+3: 46%) had secondary AML. The major-
ity of patients (FLAM: 77% vs. 7+3: 68%) had one or more
poor-risk features, defined as: 1) WBC >50x109/L; 2)
adverse genetics (ie. adverse cytogenetics and/or FLT3-
ITD mutation); and/or 3) secondary AML. 
Toxicity
Grade 3 or more toxicities were similar in both arms
(Table 2). Although the rates of tumor lysis syndrome
(TLS) were similar between FLAM and 7+3 (FLAM: 8% vs.
7+3: 7%), there were 2 early deaths on the FLAM arm due
to TLS (compared with 1 early death on 7+3), and 3 grade
4 TLS toxicities on FLAM: acute kidney injury requiring
dialysis (n=2), and cytokine release syndrome (n=1).
While there was no significant difference in treatment-
related mortality between both arms (day 60 mortality:
FLAM: 10%, 95%CI: 5%-17% vs. 7+3: 4%, 95%CI: 0-
12%; P=0.22), the majority (8 of 11) of early deaths on
FLAM were in patients aged 60 years or over. Causes of
early mortality (day 60 mortality) on FLAM included
refractory leukemia (n=4), infection/sepsis (n=3), TLS
(n=2), multi-organ failure (n=1), and gastrointestinal (GI)
bleed (n=1). Causes of early mortality on 7+3 included
refractory leukemia (n=1) and TLS (n=1). 
Time to full hematologic recovery (ANC >1x109/L and
platelet count >100x109/L) for all patients who achieved
CR was similar for FLAM (37 days, 95%CI: 34-40 days)
and 7+3 (34 days, 95%CI: 32-37 days) (P=0.30). Patients
who received 5+2 (n=13) had a median time from start of
initial therapy to full hematologic recovery of 49 days.
Clinical outcomes
FLAM led to a 70% CR rate (71 CR + 5 CRi; 95%CI:
60%-78%), while 7+3 led to a 46% CR rate (25 CR + 1
CRi; 95%CI: 33%-60%); odds ratio = 2.64, 95%CI: 1.29-
5.45, one-sided P=0.003 (Table 3). The treatment effect
was of similar magnitude and significance after controlling
for the randomization stratification factors (odds ratio =
2.94, 95%CI: 1.44-5.99, one-sided P=0.001). Thirteen of
56 (23%) patients on the 7+3 arm received 5+2 for evi-
dence of residual leukemia on day 14 (median % cellular-
ity: 10%, range: 5%-50%; median % blasts: 33%, range:
12%-90%). Six of 13 (46%) patients achieved CR [includ-
ing one complete remission with incomplete hematologic
recovery (CRi)] after receiving 5+2. A comparison of CR
rates between FLAM and 7+3+/-5+2 was 70% (95%CI:
60%-78%) versus 57% (95%CI: 43%-70%), respectively
(one-sided P=0.08). 
A day 14 BM biopsy was performed on 102 of 109
FLAM patients and 55 of 56 7+3 patients (Table 4).
Residual leukemia on day 14 was significantly less with
FLAM compared with 7+3 (25%, 95%CI: 17-35% vs.
44%, 95%CI: 30%-58%, respectively; P=0.03). Patients in
CR received diverse post-induction treatment strategies
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Table 1. Patients’ characteristics.
                                                      FLAM (n=109)             7+3 (n=56)
                                                             N (%)                         N (%)
Age- median (range)                                59 (19-70)                      60 (22-69)
Age ≥50                                                         82 (75%)                        42 (75%)
Age ≥60                                                         48 (44%)                        31 (55%)
Male                                                               61 (56%)                        31 (55%)
Adverse genetics2                                       58 (58%)                        27 (55%)
FLT3-ITD mutation                                     13 (14%)                         6 (15%)
Adverse cytogenetics                                48 (44%)                        21 (38%)
Complex cytogenetics                               30 (28%)                        16 (29%)
Monosomal cytogenetics                         24 (22%)                        12 (21%)
NPM1 mutation                                           26 (29%)                        10 (25%)
ELN risk group
Favorable                                                      17 (16%)                         8 (14%)
Intermediate-1                                            32 (29%)                        22 (39%)
Intermediate-2                                            12 (11%)                          5 (9%)
Adverse                                                         48 (44%)                        21 (38%)
Secondary AML                                           52 (48%)                        26 (46%)
Treatment-related                                     15 (14%)                          4 (7%)
Prior hematologic disorder                     37 (34%)                        22 (39%)
WBC >50x109/L                                                                        13 (12%)                          5 (9%)
No poor-risk features3                                                  25 (23%)                        18 (32%)
≥1 poor-risk feature                                  84 (77%)                        38 (68%)
≥2 poor-risk features                                34 (31%)                        20 (36%)
Site
Johns Hopkins                                         46 (42%)                        22 (39%)
University of North Carolina                15 (14%)                         8 (14%)
Mayo Clinic- MN                                      15 (14%)                          5 (9%)
BMT of GA                                                11 (10%)                         7 (12%)
Vanderbilt                                                   8 (7%)                            3 (5%)   
Moffitt                                                          3 (3%)                            4 (7%)
VCU                                                              3 (3%)                            3 (5%)
Baylor- Dallas, TX                                      3 (3%)                            3 (5%)
Mayo Clinic- AZ                                          4 (4%)                            1 (2%)
University of MD                                       1 (1%)                            0 (0%)
There were no significant differences between both arms for all of the patients’ charac-
teristics; 2adverse genetics included patients with adverse cytogenetics according to
ELN risk criteria14 and/or FLT3-ITD mutations; 3poor-risk features defined by: 1) WBC
>50x109/L) Adverse genetics (adverse cytogenetics and/or FLT3-ITD mutation), 3)
Secondary AML (treatment-related or AML from antecedent hematologic disorder).
Table 2. Toxicity comparisons.
Grade ≥3 toxicity FLAM (n=109) 7+3 (n=56) P
Tumor lysis syndrome 9 (8%)1 4 (7%)2 >0.99
Myocardial dysfunction 8 (7%) 3 (5%) 0.75
GI toxicity 12 (11%)3 5 (9%) 0.79
Hepatic dysfunction 23 (21%) 13 (23%) 0.84
Infection 38 (35%)4 21 (38%) 0.74
Pulmonary toxicity 8 (7%) 4 (7%) >0.99
Renal toxicity 3 (3%) 1 (2%) >0.99
Thromboembolic events 3 (3%) 1 (2%) >0.99
Febrile neutropenia events 52 (48%) 25 (45%) 0.74
Day 30 mortality 5 (5%) 1 (2%) 0.67
Day 60 mortality 11 (10%) 2 (4%) 0.22
TLS: tumor lysis syndrome; GI: gastrointestinal; 12 early deaths due to TLS; 
21 early death due to TLS; 31 early death due to GI bleed; 43 early deaths due to sepsis. 
based on physician/institution preference. Of the 76
FLAM patients who achieved CR, 35 (46%) underwent
FLAM consolidation, 21 (28%) high-dose cytarabine
(HiDAC) consolidation, 13 (17%) early allogeneic SCT
without consolidation, 5 (7%) had poor performance sta-
tus preventing further therapy, one had early relapse, and
one underwent clofarabine treatment for persistent cyto-
genetic abnormalities. Of the 32 CR patients on 7+3 (with
or without 5+2), 26 (81%) underwent HiDAC consolida-
tion, 3 (9%) early allogeneic SCT without consolidation, 2
(6%) had poor performance status preventing further ther-
apy, and one patient refused further therapy. A total of 82
(50%) patients underwent allogeneic SCT (FLAM: 55 of
109=51%; 7+3: 27 of 56=48%), and one patient under-
went an autologous SCT in CR on the 7+3 arm. Of the 83
patients who underwent a SCT (autologous + allogeneic),
myeloablative conditioning was performed on 44% and
64% of FLAM and 7+3 patients, respectively, based on
institution preference. Donors on the FLAM arm included
matched related (n=17), matched unrelated (n=19), hap-
loidentical (n=16), and cord blood (n=3) donors. Donors
on the 7+3 arm included matched related (n=7), matched
unrelated (n=14), haploidentical (n=5), and cord blood
(n=1) donors. Relapses were similar in patients who
underwent SCT in CR1 (FLAM: 32% vs. 7+3: 38%).
Subset analyses
Although not powered to demonstrate significance,
FLAM increased CR rates across different risk groups, as
seen in exploratory ad hoc analyses (Figure 2). When test-
ing for heterogeneity of treatment effect, patients under 50
years of age derived greater benefit from FLAM versus one
cycle of 7+3 (CR rates: FLAM: 96% vs. 7+3: 57%; odds
ratio = 19.5, 95%CI: 2.03-187.0) compared to those aged
50 years or over (FLAM: 61% vs. 7+3: 43%; odds ratio =
2.08, 95%CI: 0.98-4.43; P for interaction = 0.04). This dif-
ference also persisted for FLAM versus 7+3+/-5+2 (P for
interaction = 0.007). Those with no poor-risk features also
saw greater benefit from FLAM (CR rates: FLAM: 100%
vs. 7+3: 72%; odds ratio = 20.8, 95%CI: 1.07-405.0) when
compared with one or more poor-risk features (FLAM:
61% vs. 7+3: 34%; odds ratio = 2.9, 95%CI: 1.32-6.0; P for
interaction = 0.04). Notably, patients with secondary AML
(CR rates: FLAM: 60% vs. 7+3: 35%) derived similar ben-
efit from FLAM as de novo AML (FLAM: 79% vs. 7+3:
57%). 
Overall survival and event-free survival outcomes
Median follow up was 553 days (range: 1-1217 days). To
date, relapses were similar for FLAM and 7+3 (43% vs.
50%, respectively). There was no significant OS differ-
ence between FLAM and 7+3: median OS = 17.5 months,
95%CI: 12.7-25.4 months, on FLAM versus 22.2 months,
95%CI: 16.2-40.0 months, on 7+3 (P=0.39) (Figure 3A).
Two-year OS on FLAM was 50% versus 59% on 7+3.
Although not significantly different, there was an appar-
ent clinical improvement with FLAM with a median EFS =
9.7 months (95%CI: 5.0-11.7 months) on FLAM versus 3.4
months (95%CI: 1.3-13.3 months) on 7+3 (P=0.15) (Figure
3B). 
Overall, 65 (60%) patients died on the FLAM arm com-
pared with 32 (57%) deaths on the 7+3 arm. Causes of
death on the FLAM arm included refractory leukemia
(n=43), sepsis/infection (n=8), allogeneic SCT complica-
tions (n=6), hemorrhage/coagulopathy (n=3), TLS (n=2),
stroke (n=1), multi-organ failure (n=1), and unknown
causes (n=1), whereas causes of death on 7+3 included
refractory leukemia (n=26), allogeneic SCT complications
(n=4), TLS (n=1), and sepsis/infection (n=1). In addition,
13 (17%) patients on FLAM died while in CR compared
with 3 (10%) on 7+3. Causes of death in CR on FLAM
included allogeneic SCT complications (n=6), infections
(n=3; including one patient who died of E. coli sepsis dur-
ing HiDAC consolidation), progressive bone marrow fail-
ure (n=1), presumed central nervous system (CNS)
leukemia (n=1), intracerebral hemorrhage (n=1), and
unknown causes (n=1). Causes of death in CR on 7+3
included allogeneic SCT complications (n=2), and
sepsis/infection (n=1). 
Discussion
The main study objective of this phase II trial was to
assess the relative activity of FLAM compared with 7+3 in
order to determine whether there was justification for fur-
ther development of FLAM based on CR rate. The study
findings support the hypothesis that FLAM induction
leads to superior CR rates compared with 7+3 therapy
FLAM vs. 7+3 in newly diagnosed AML
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Table 3. Response comparisons.
Response FLAM 7+3 P* 7+3 +/- 5+2 P*
(n=109) (n=56) (n=56)
CR/CRi- n. (%) 76 (70%) 26 (46%) 0.003 32 (57%) 0.08
Failure to achieve CR- n. (%) 26 (24%) 29 (52%) 23 (41%)
Early death- n. (%) 7 (6%) 1 (2%) 1 (2%)
*P values were derived from one-sided Fisher’s exact test.CR: complete remission; CRi: complete remission with incomplete hematologic recovery.
Table 4. Day 14 bone marrow biopsy comparisons.
FLAM 7+3 P1
(n=109) (n=56)
Day 14 BM biopsy results 102 (94%)2 55/56 (98%)3
Residual leukemia on day 14 26 (25%) 24 (44%) 0.03
Achievement of CR 10 (38%) 10 (42%)4
5+2 given N/A 13 (54%)
No residual leukemia on day 14 76 (75%) 31 (56%) 0.03
Achievement of CR 63 (83%) 22 (71%)
1P value derived from a two-sided Fisher’s exact test and included for descriptive pur-
poses only; 27 of 109 patients on FLAM arm did not receive a day 14 BM biopsy due to:
Early death (n=4); logistical concerns and/or patient refusal (n=2); patient in Intensive
Care Unit (n=1); 31 of 56 patients on 7+3 arm did not receive a day 14 BM biopsy due
to: early death; 4of the 24 patients on the 7+3 arm with residual leukemia on day 14:
10 (42%) achieved a CR (6/13 who received 5+2, 4/11 who did not receive 5+2). 
(70% vs. 46%; P=0.003) in patients with intermediate and
adverse-risk cytogenetics. The cycle 1 CR rate was chosen
as a more specific indicator of relative activity between
the 2 regimens because of variations in the approach fol-
lowing one cycle of induction therapy in practice. For
instance, many leukemia clinicians utilize a re-induction
strategy (ie. 5+2) in some patients with persistent disease
on day 14 after 7+3 induction. In contrast, FLAM is not
intensified on the basis of early BM biopsy findings. We
considered it to be important to compare the FLAM regi-
J.F. Zeidner et al.
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Figure 2. Subset analyses. Forest plot of odds ratios for complete remission in patient subgroups, plotted on a log scale. P values were derived
from likelihood ratio tests of logistic regression models for interaction between treatment: (A) FLAM vs. 7+3 and (A) FLAM vs. 7+3+/-5+2, and
patient subgroup on complete remission. To provide information about patients in the ‘no poor-risk features’ subgroup, 0.5 was added to all
cell counts in this analysis for calculating odds ratios and 95% confidence intervals.
A
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men to an appropriate contemporary standard control reg-
imen of 7+3; thus, we allowed a re-induction strategy (ie.
5+2) in those patients with residual leukemia on day 14, as
recommended by the National Comprehensive Cancer
Network Guidelines in AML.18 There are a number of con-
founders when determining whether to give a second
cycle of induction, such as patient age, performance status,
toxicities, and day 14 BM findings.19 Therefore, a second
cycle of induction was recommended, but not mandated,
in those patients with residual leukemia on day 14. The
comparison of FLAM to 7+3+/-5+2 (CR rates: 70% vs.
57%; P=0.08) also substantiates the improved efficacy
with FLAM and further supports the development of this
regimen.  
The CR rates seen on this study were lower than other
recently reported phase III studies in AML due to differ-
ences in the patient populations studied.16,20,21 Patients with
favorable-risk cytogenetic features (ie. CBF AML) were
excluded on this study. In addition, newly diagnosed eld-
erly AML patients were included on this study up to 70
years of age, whereas other trials only included patients up
to 60 years of age.16,20,21 Forty-seven percent of patients on
this study had secondary AML, a subgroup with poor out-
comes.22 A larger proportion of patients had adverse-risk
cytogenetics (41% total) when compared with other con-
temporary phase III studies in AML.16,20,21 The relatively
low CR rates seen on the 7+3 arm of this study were con-
sistent with other recent reports in similar non-favorable
risk patient populations.23,24 
Importantly, there was no difference in overall toxicity
between FLAM and 7+3. TLS was a major concern given
the high rates of TLS with flavopiridol in chronic lympho-
cytic leukemia25-27 and consistent 7%-10% incidence of
grade 3 or more TLS in our prior phase II studies.10-12 Three
patients treated with FLAM on this study had grade 4 TLS,
and 2 patients died due to complications of TLS. Patients
with WBC more than 20x109/L, monocytic phenotypes
(ie. M4/M5, or arising from pre-existing MPN), and base-
line renal dysfunction appear to predispose to grade 4 or
more TLS with FLAM. Though all patients received allop-
urinol and sevelamer prophylaxis, it may be necessary to
use rasburicase and other supportive care measures to
blunt cytokine release syndrome (eg. steroids) in order to
decrease the severity of TLS in future trials with FLAM. 
In addition, older age (>60 years) appears to predispose
to FLAM toxicity. Although overall treatment-related mor-
tality rates were similar between FLAM and 7+3, 8 of 11
early deaths (<60 days) on FLAM occurred in patients aged
60 years or over. On subset analyses, younger patients had
higher CR rates with FLAM compared with 7+3, and this
difference remained statistically significant after 7+3+/-
5+2.
A major question in the management of AML patients is
whether or not to give more chemotherapy for a day 14
BM biopsy revealing residual leukemia. There is, unfortu-
nately, a lack of a consistent approach in managing these
patients. Moreover, some patients with residual leukemia
on a day 14 BM biopsy after 7+3 induction will ultimately
achieve CR and may not need additional induction thera-
py.28-30 There is considerable investigator bias regarding
whether or not to give a second cycle of induction therapy
for patients with residual leukemia on day 14.19 In our
study, 24 patients on the 7+3 arm had residual leukemia
on day 14, but only 13 (54%) received 5+2, and 6 of 13
(46%) achieved CR (compared with 4 of 11 without 5+2).
The proportion of patients achieving a CR with a second
cycle of induction was similar to other reports.16,30
Although Rowe et al.31 reported that adults who achieve a
CR after one or two courses of induction therapy have
similar overall outcomes, this analysis was retrospective,
and the patients included on this analysis received an iden-
tical course of induction therapy (ie. 7+3), as opposed to
5+2 for day 14 residual leukemia. In contrast, the GOE-
LAMS study group32 performed a multicenter prospective
study in which a second induction course was given to
patients with 5% or more blasts on a day 15 BM biopsy,
and showed that those with residual leukemia on day 15
had significantly worse outcomes, even after a second
induction course. In the present study, patients on the
FLAM arm did not receive more intensive therapy in the
presence of residual leukemia on day 14, and a proportion
of those (38%) still achieved CR.
Secondary AML represents a subgroup of patients with
an extremely poor outcome who may benefit from FLAM
induction. Secondary AML can be confirmed based on his-
FLAM vs. 7+3 in newly diagnosed AML
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Figure 3. Kaplan-Meier estimates of overall survival (OS) and event-
free survival (EFS). (A). OS for the entire cohort and treatment arm
measured by Kaplan-Meier methodology. OS is defined as the date of
randomization to date of last follow up or death. (B). EFS for the
entire cohort and treatment arm measured by Kaplan-Meier method-
ology. EFS is defined as time from randomization to persistent AML
after one cycle of induction therapy, relapse, death, or date of last fol-
low up (censored).  
A
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tory alone in most cases. While 60% of patients with sec-
ondary AML in this current study achieved CR, we have
now treated 158 newly diagnosed secondary AML
patients with FLAM across all 4 phase II studies with an
overall CR rate of 66% (105 of 158).10-12 The similar effect
with FLAM in secondary versus de novo AML highlights
FLAM activity in secondary AML, despite the overall
decreased response rates and poor outcomes seen in this
subpopulation. Moreover, although small numbers, all 6
patients with secondary AML and aged under 50 years
treated with FLAM achieved a CR on this study (com-
pared to 1 of 3 patients with secondary AML and under 50
years of age achieving a CR on 7+3). Thus, these data sub-
stantiate the benefit of FLAM in secondary AML, particu-
larly in younger patients, and compare favorably to the
promising findings seen with CPX-351.23 
Despite the significant improvement in response rates
seen with FLAM, our study did not show a difference in
OS. These findings must be interpreted cautiously as the
study was not powered to detect an OS difference. Other
recently performed randomized studies in AML have also
reported improved CR rates without OS advantage.33
Moreover, lack of an OS advantage from a randomized
phase II study aimed primarily to assess activity does not
diminish the pertinence of these findings. It also reinforces
the importance of a larger randomized phase III study
specifically powered to detect an OS advantage, as evi-
denced by the finding that the OS of the 56 patients on the
7+3 arm of this poor-risk patient population was signifi-
cantly better than the results of recently reported phase III
studies.16,20,21,34 An additional limitation of the OS/EFS
analyses on this study was the lack of standardized post-
induction treatment strategies in both arms. FLAM was
initially developed as two cycles (induction and consolida-
tion therapy) in patients who achieve CR but post-induc-
tion treatment for both arms in this study was not defined.
For example, only 46% of CR patients on FLAM received
FLAM consolidation, while 28% received HiDAC, and
17% received early allogeneic SCT without consolidation
therapy. In addition, post-remission transplantation condi-
tioning therapies and donor selections were also variable.
This lack of a consistent treatment approach for patients
who achieve CR is a major challenge in drug development
in AML. It will be essential for these post-induction treat-
ment strategies to be standardized for phase III studies in
order to truly verify whether FLAM induction can
improve overall outcomes compared with 7+3. Given the
inherent variability and unclear utility of a second cycle of
induction with 7+3, a phase III study comparing FLAM to
one cycle of 7+3 (without early re-induction therapy)
would eliminate any potential biases of re-treatment.   
In conclusion, FLAM represents a promising induction
regimen for AML patients with intermediate- and adverse-
risk cytogenetic features. Our findings reveal that FLAM
induction leads to superior CR rates when compared with
7+3. On subset analyses, younger patients (<50 years), and
those with no poor-risk features, appeared to benefit more
from FLAM than their 7+3 counterparts. Moreover, FLAM
demonstrated promising activity in secondary AML.
While the data clearly demonstrate that FLAM induction
leads to superior CR rates compared with 7+3 alone, rig-
orous clinical trial designs are required to determine OS
differences, particularly among select subgroups such as
secondary AML.  
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